ArticleBMC health services research2026
Eligible but missing out: a qualitative study of access to COVID-19 antivirals in Australia.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundOral antiviral medication is available free of charge to Australians with SARS-CoV-2 infection who meet specific eligibility criteria. Health services and systems are targeted to support vulnerable populations, but not all eligible people received antivirals prior to hospitalisation. To expand the evidence base of social and behavioural insights in infectious disease emergencies and inform future pandemic responses, we sought to understand why people at high risk of hospitalisation with COVID-19 did not access antivirals.
methodsWe conducted 29 semi-structured interviews with people who were eligible for antivirals but did not receive them, and who were subsequently hospitalised with COVID-19. Interview questions explored all levels of influence on antiviral uptake from intrapersonal to policy, via the patients’ perspective. Analysis blended deductive and inductive approaches and resulting themes were categorised into the factors of the Capability-Opportunity-Motivation-Behaviour (COM-B) model. FINDINGS/
resultsMost participants lacked the capability to access antivirals through primary care. The key impediment was a lack of awareness about their existence or availability. In addition, many did not have sufficient opportunity, usually due to an inability to access primary care services in a timely manner. Almost all participants were highly conscious of their health and risks posed by their pre-existing conditions. Of those who were motivated to seek antivirals, reasons included preventing severe symptoms and limiting their time off work. Participants described situational mistrust in the provision of primary healthcare as structural changes made it harder or more expensive to access.
conclusionTo improve antiviral uptake during an infectious disease emergency, policy makers need to ensure medication access to those eligible but also provide good motivations to take them by promoting them as a preventative measure. This can be done by targeted government communication and measures that address healthcare system inequities through better access to and quality of primary care for vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.